Device Trial Radar · NCT07316192
Pelashield™ PainGuard™ vs Restrata® in HS Surgery
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Dec 1, 2025
Primary completion
Sep 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- Rutgers, The State University of New JerseyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 5, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hidradenitis Suppurativa (HS) is a long-lasting skin condition that causes painful lumps and infections. In severe cases, patients need surgery to remove the affected skin. After surgery, a wound dressing called a wound matrix is placed over the area to help the skin heal. This study will compare two different wound matrices: Restrata®, which is the current standard treatment. Pelashield™ PainGuard™, a newer dressing that contains silver to reduce bacteria and lidocaine to help with pain. The goal of this research is to find out if Pelashield™ PainGuard™ helps patients heal better after surgery than Restrata®. We will look at: How quickly healthy granulation tissue (new healing tissue) forms How soon the wound is ready for the second surgery to apply a skin graft How often infections happen after surgery How much narcotic (opioid) pain medication patients need after surgery Patients who receive Pelashield™ PainGuard™ will be enrolled in the study going forward (prospective group). Patients who previously had surgery with Restrata® will be included through a review of their medical records (retrospective group). No additional procedures will be done outside of standard surgical care.
Conditions
- Hidradenitis Suppurativa (HS)
Interventions
Pelashield PainguardDevice
This is the only intervention being used in this study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Postoperative Opioid Analgesic UsageTime frame: Period 1: After Stage 1 excision through day before Stage 2 closure (up to 8 weeks starting one day after surgery 1) Period 2: Stage 2 closure through 30 days post-Stage 2
- ReCell Skin Graft IncorporationTime frame: Assessment performed at 14 days (±3 days) post-Stage 2 during routine clinic follow-up
- Surgical Site Infection (SSI) During Wound Bed PreparationTime frame: After Stage 1 excision through day before Stage 2 closure (up to 8 weeks starting one day after surgery 1)
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital
Newark, New Jersey · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.